Palladon Retard (Hydromorphone Hydrochloride)

Hydromorphone hydrochloride, the active ingredient in Palladon Retard, is an opioid analgesic presented as a controlled‑release formulation for oral use. It is indicated for the management of moderate to severe pain in adult patients when continuous, around‑the‑clock therapy is required. GNH USA supplies Palladon Retard as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Hydromorphone hydrochloride acts on the central nervous system to provide potent analgesia for several pain‑related conditions. - Cancer‑related pain: provides continuous relief of severe pain in patients with malignant disease. - Post‑operative pain: maintains steady analgesic levels after major surgery when oral intake is possible. - Chronic non‑cancer pain: offers round‑the‑clock control for severe, persistent pain unresponsive to weaker opioids.

Adverse reactions may range from mild to life‑threatening and should be monitored throughout therapy.

Common Side Effects: - Constipation: reduced gastrointestinal motility leading to hard stools. - Nausea: sensation of queasy stomach, often transient. - Drowsiness: mild sedation or feeling of fatigue. - Dry mouth: reduced salivary flow causing oral discomfort. - Sweating: increased perspiration without exertion. - Dizziness: light‑headed sensation, especially when standing quickly.

Serious or Rare Side Effects: - Respiratory depression: slowed or shallow breathing that can be fatal. - Severe hypotension: marked drop in blood pressure leading to fainting. - Opioid dependence or addiction: compulsive use despite harmful consequences. - Withdrawal syndrome: symptoms upon abrupt discontinuation. - Anaphylaxis: rare severe allergic reaction with hives, swelling, and airway compromise. - QT prolongation: abnormal heart rhythm detectable on ECG.

When prescribing Palladon Retard, clinicians should evaluate patient history and monitor for potential complications. - Assess renal and hepatic function: dose may need adjustment in impairment. - Evaluate for respiratory disorders: patients with COPD or sleep apnea are at higher risk. - Review concomitant CNS depressants: combined use can enhance sedation and respiratory depression. - Monitor for signs of opioid misuse: implement risk‑mitigation strategies. - Educate patients on proper disposal: use take‑back programs to prevent diversion. - Store at ambient temperature: keep below 25°C, retain original packaging, protect from moisture and direct sunlight.

Hydromorphone can interact with several drug classes, altering its safety profile.

Major Interactions (Avoid): - Benzodiazepines: synergistic CNS depression increasing risk of respiratory failure. - Barbiturates: potentiate sedative effects and may precipitate profound hypotension. - Muscle relaxants: enhance central nervous system depression.

Moderate Interactions (Monitor Closely): - Antidepressants (SSRIs, SNRIs): may increase serotonin levels, raising serotonin syndrome risk. - Antihistamines: additive sedation. - CYP3A4 inhibitors (e.g., ketoconazole): can raise hydromorphone plasma concentrations.